{"product_id":"glow-blend","title":"GLOW Blend (GHK-Cu + BPC-157 + TB-500)","description":"\u003ch2 style=\"font-size:18px;font-weight:600;margin:0 0 12px\"\u003eCompound Overview\u003c\/h2\u003e\n\u003cdiv style=\"background:#faf2e2;border:1px solid #eeddbc;border-left:4px solid #8a6318;border-radius:14px;padding:16px 18px;margin:0 0 22px\"\u003e\n\u003cp style=\"margin:0 0 8px;font-size:15px;color:#8a6318;font-weight:600\"\u003eIndependent certificate published — in stock\u003c\/p\u003e\n\u003cp style=\"margin:0;font-size:15px;color:#16201a;line-height:1.65\"\u003eThe GLOW Blend is a \u003cstrong\u003emulti-peptide research preparation\u003c\/strong\u003e. The independent certificate for lot glow70-0626-01 is now published — an \u003cstrong\u003eHPLC purity of 99.469%\u003c\/strong\u003e, with the \u003cstrong\u003eidentity and content of each of the three components\u003c\/strong\u003e confirmed separately — and is posted with its lot number on our \u003ca href=\"\/pages\/lab-results\"\u003elab results page\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cp style=\"margin:0 0 16px;font-size:15px;line-height:1.65;color:#16201a\"\u003e\u003cstrong\u003eThe GLOW Blend combines three of the most heavily studied compounds in skin, connective-tissue and repair research — the copper tripeptide GHK-Cu, the gastric pentadecapeptide BPC-157, and the actin-binding peptide TB-500 (thymosin β4) — co-lyophilised in a single vial for laboratory research use only. The configuration is GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg, 70 mg total, confirmed against this lot's certificate of analysis.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 16px;font-size:15px;line-height:1.65;color:#5a6157\"\u003eThis is a \u003cstrong style=\"color:#16201a\"\u003eblend, not a single molecule\u003c\/strong\u003e, and that one fact governs everything else on this page. Retatrutide is one 39-residue chain that happens to engage three receptors; GLOW is three chemically unrelated peptides sharing a vial. A blend has no molecular formula, no molecular weight and no single purity number, because those quantities are only defined for one compound at a time. What a responsible blend listing can state is which three peptides are present, how much of each, and how each one is verified. That is the structure of this page, and it is the reason the headline figure here is a per-component certificate rather than a single assay percentage.\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 16px;font-size:15px;line-height:1.65;color:#5a6157\"\u003e\u003cstrong style=\"color:#16201a\"\u003eGHK-Cu — the copper-tripeptide arm.\u003c\/strong\u003e GHK-Cu is glycyl-L-histidyl-L-lysine (Gly-His-Lys) complexed with copper(II): molecular formula C\u003csub\u003e14\u003c\/sub\u003eH\u003csub\u003e22\u003c\/sub\u003eCuN\u003csub\u003e6\u003c\/sub\u003eO\u003csub\u003e4\u003c\/sub\u003e, CAS 89030-95-5, molecular weight approximately 403.9 g\/mol for the complex (the metal-free tripeptide is C\u003csub\u003e14\u003c\/sub\u003eH\u003csub\u003e24\u003c\/sub\u003eN\u003csub\u003e6\u003c\/sub\u003eO\u003csub\u003e4\u003c\/sub\u003e, 340.4 g\/mol, CAS 49557-75-7). GHK was first isolated from human plasma by Pickart and Thaler in 1973 and identified as the tripeptide a few years later. In dermal and wound-model research it is studied for extracellular-matrix remodelling — stimulation of collagen and glycosaminoglycan synthesis in fibroblast cultures (Maquart et al., \u003cem\u003eFEBS Lett\u003c\/em\u003e 1988;238(2):343-346, PMID 3220688) — alongside antioxidant and copper-transport roles. It is the component that gives GLOW its skin-and-matrix character, and the reason a reconstituted blend takes on a faint blue tint.\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 16px;font-size:15px;line-height:1.65;color:#5a6157\"\u003e\u003cstrong style=\"color:#16201a\"\u003eBPC-157 — the soft-tissue arm.\u003c\/strong\u003e BPC-157 is a synthetic 15-residue peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) whose sequence corresponds to a fragment of a \"body protection compound\" described in gastric juice: molecular formula C\u003csub\u003e62\u003c\/sub\u003eH\u003csub\u003e98\u003c\/sub\u003eN\u003csub\u003e16\u003c\/sub\u003eO\u003csub\u003e22\u003c\/sub\u003e, CAS 137525-51-0, molecular weight approximately 1419.6 g\/mol, PubChem CID 9941957. The published research on it is almost entirely in rodents and in vitro, and centres on angiogenic signalling — including VEGFR2 pathway activation (Hsieh et al., \u003cem\u003eJ Mol Med\u003c\/em\u003e 2017;95(3):323-333, PMID 27696202) — and on tendon, ligament and muscle models of fibroblast outgrowth and cell migration (Chang et al., \u003cem\u003eJ Appl Physiol\u003c\/em\u003e 2011;110(3):774-780, PMID 21030672).\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 16px;font-size:15px;line-height:1.65;color:#5a6157\"\u003e\u003cstrong style=\"color:#16201a\"\u003eTB-500 — the actin\/migration arm.\u003c\/strong\u003e \"TB-500\" is a research-market name tied to thymosin β4 (Tβ4), a 43-residue, ~4.9 kDa G-actin-sequestering protein: full-length formula C\u003csub\u003e212\u003c\/sub\u003eH\u003csub\u003e350\u003c\/sub\u003eN\u003csub\u003e56\u003c\/sub\u003eO\u003csub\u003e78\u003c\/sub\u003eS, CAS 77591-33-4, molecular weight approximately 4963.4 Da. It is studied for actin regulation, endothelial and keratinocyte migration and angiogenesis in repair models (Goldstein et al., \u003cem\u003eTrends Mol Med\u003c\/em\u003e 2005;11(9):421-429, PMID 16099219; Malinda et al., \u003cem\u003eJ Invest Dermatol\u003c\/em\u003e 1999;113(3):364-368, PMID 10469335). There is a real ambiguity here, addressed in the FAQ: the name \"TB-500\" historically denotes the short actin-binding fragment Ac-LKKTETQ (~889 Da), but most research-grade material is the full Tβ4 sequence. The published COA states which form this lot contains.\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 16px;font-size:15px;line-height:1.65;color:#5a6157\"\u003e\u003cstrong style=\"color:#16201a\"\u003eWhy these three together.\u003c\/strong\u003e The grouping is studied because the three mechanisms are \u003cstrong style=\"color:#16201a\"\u003ecomplementary rather than redundant\u003c\/strong\u003e: GHK-Cu acts on the matrix side (collagen, elastin and glycosaminoglycan signalling, copper delivery, antioxidant pathways), BPC-157 on angiogenic and cytoprotective signalling in connective tissue, and TB-500 on cytoskeletal dynamics and cell migration. A researcher modelling dermal or connective-tissue repair can expose a single system to all three pathways at once instead of reconstituting and co-administering three separate vials, which removes a set of pipetting and lot-matching variables from the experiment. That is the entire rationale: GLOW is a convenience format for parallel-pathway repair research, not a product with any combined effect demonstrated in a clinical trial — no such trial of this three-peptide combination exists.\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 16px;font-size:15px;line-height:1.65;color:#5a6157\"\u003e\u003cstrong style=\"color:#16201a\"\u003eHow a blend is verified.\u003c\/strong\u003e A single peptide is reported as one HPLC area-percent purity number against one identity confirmation. A blend cannot be, because a single percentage across three molecules of different mass and different UV response would be meaningless — it would not tell you whether the 10 mg of BPC-157 is actually present or whether the copper complex has dissociated. Instead, verification confirms the \u003cstrong style=\"color:#16201a\"\u003eidentity and content of each component separately\u003c\/strong\u003e, typically by HPLC with mass-spectrometric identity confirmation, so each of the three peptides is shown to be present and quantified against its labelled mass. This is the same approach we apply to our other multi-component products — the \u003ca href=\"\/products\/healing-blend-10mg-bpc-157-tb-500\"\u003eBPC-157 + TB-500 Healing Blend\u003c\/a\u003e, the Wolverine blend and the \u003ca href=\"\/products\/cjc-1295-ipamorelin\"\u003eCJC-1295 + Ipamorelin\u003c\/a\u003e blend. The published certificate for this lot reports per-component identity and content, and also records an overall HPLC purity of 99.469%.\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 16px;font-size:15px;line-height:1.65;color:#5a6157\"\u003e\u003cstrong style=\"color:#16201a\"\u003eThe honest evidence and regulatory frame.\u003c\/strong\u003e None of the three components is approved for human use by any regulator, and the blend has no DIN. The published evidence for all three is dominated by in-vitro and rodent work; there are no adequate human efficacy trials for BPC-157 or for the TB-500 fragment, and GHK-Cu's human data is largely topical cosmetic work rather than injectable therapeutic data. Health Canada's public advisory of 9 April 2026 (identification number RA-81874) names \u003cstrong style=\"color:#16201a\"\u003eGHK-Cu, BPC-157 and TB-500 individually\u003c\/strong\u003e among unauthorised peptides sold online, states that they have not been assessed for safety, efficacy or quality, and states explicitly that labelling a product \"For Research Use Only\" does not make it legal to sell for human use. Two of the three components are also prohibited in sport: BPC-157 under WADA class S0 and thymosin β4 under class S2. We reproduce these facts rather than bury them. There is no research guide for the blend as a whole; for one of its three components, see our \u003ca href=\"\/blogs\/research\/ghk-cu-canada\"\u003eGHK-Cu research guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003cdiv style=\"margin-top:20px;margin-bottom:4px;padding:14px 16px;background:#f0faf5;border-left:4px solid #0f6e56;border-radius:0 8px 8px 0\"\u003e\u003cp style=\"margin:0;font-size:14px;color:#1a1a1a\"\u003e\u003cstrong\u003eFor laboratory and research use only.\u003c\/strong\u003e Not for human consumption, veterinary use, or therapeutic application. Not approved by Health Canada. No DIN. We do not provide preparation, dilution or administration guidance for any compound we sell.\u003c\/p\u003e\u003c\/div\u003e\n\u003ch2 style=\"font-size:16px;font-weight:600;margin:26px 0 10px\"\u003eSpecifications\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:15px;line-height:1.55\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600;width:38%\"\u003eCompound\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eGLOW Blend — GHK-Cu + BPC-157 + TB-500, co-lyophilised multi-peptide vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eComponents \u0026amp; amounts\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eGHK-Cu \u003cstrong\u003e50 mg\u003c\/strong\u003e + BPC-157 \u003cstrong\u003e10 mg\u003c\/strong\u003e + TB-500 \u003cstrong\u003e10 mg\u003c\/strong\u003e = \u003cstrong\u003e70 mg total\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eCompound class\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eMulti-peptide research blend (copper tripeptide + regenerative\/repair peptides); not a single molecular entity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eGHK-Cu molecular data\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eCopper tripeptide-1 (Gly-His-Lys · Cu\u003csup\u003e2+\u003c\/sup\u003e); C\u003csub\u003e14\u003c\/sub\u003eH\u003csub\u003e22\u003c\/sub\u003eCuN\u003csub\u003e6\u003c\/sub\u003eO\u003csub\u003e4\u003c\/sub\u003e; CAS 89030-95-5; MW ≈ 403.9 g\/mol (complex); PubChem CID 378611. Metal-free GHK: C\u003csub\u003e14\u003c\/sub\u003eH\u003csub\u003e24\u003c\/sub\u003eN\u003csub\u003e6\u003c\/sub\u003eO\u003csub\u003e4\u003c\/sub\u003e, 340.4 g\/mol, CAS 49557-75-7, CID 342538\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eBPC-157 molecular data\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003ePentadecapeptide (GEPPPGKPADDAGLV); C\u003csub\u003e62\u003c\/sub\u003eH\u003csub\u003e98\u003c\/sub\u003eN\u003csub\u003e16\u003c\/sub\u003eO\u003csub\u003e22\u003c\/sub\u003e; CAS 137525-51-0; MW ≈ 1419.6 g\/mol; PubChem CID 9941957 (free base; often supplied as acetate salt)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eTB-500 molecular data\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eFull-length thymosin β4 (43 residues); C\u003csub\u003e212\u003c\/sub\u003eH\u003csub\u003e350\u003c\/sub\u003eN\u003csub\u003e56\u003c\/sub\u003eO\u003csub\u003e78\u003c\/sub\u003eS; CAS 77591-33-4; MW ≈ 4963.4 Da; PubChem CID 16130300. Fragment caveat: \"TB-500\" historically = Ac-LKKTETQ (~889 Da); COA states which form the lot contains\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eAppearance\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eLyophilised powder; pale-blue tint from the GHK-Cu copper complex. Reconstitutes to a clear-to-faint-blue solution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eReconstitution (lab)\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eSterile or bacteriostatic water for laboratory handling; see \u003ca href=\"\/products\/bacteriostatic-water-3ml\"\u003ebacteriostatic water 3ml\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eResearch applications\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eDermal fibroblast and keratinocyte models; extracellular-matrix, collagen, elastin and glycosaminoglycan signalling; in-vitro wound-closure and scratch-migration assays; angiogenesis and endothelial tube-formation models; connective-tissue (tendon\/ligament\/muscle) outgrowth models; parallel multi-pathway repair studies where three mechanisms are examined in one system; comparative work against single-component and two-component (Wolverine \/ Healing Blend) preparations; HPLC and LC-MS\/MS method development for multi-peptide mixtures\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eAssay note\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eBlend — identity and content of \u003cstrong\u003eeach component verified separately\u003c\/strong\u003e (HPLC with MS identity confirmation). Per-component COA published; the certificate also records an overall HPLC purity of 99.469% for lot glow70-0626-01\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eLot \/ COA status\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#8a6318;font-weight:600\"\u003eLot glow70-0626-01 — independent COA published (overall HPLC purity 99.469%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eCost per mg\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003e$1.71 per mg ($119.99 \/ 70 mg)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eStorage\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eLyophilised: −20 °C long-term, 2–8 °C short-term, desiccated and protected from light. After reconstitution: 2–8 °C, minimise freeze–thaw cycling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eRelated compounds\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003e\n\u003ca href=\"\/products\/ghk-cu-50mg\"\u003eGHK-Cu 50mg\u003c\/a\u003e · \u003ca href=\"\/products\/bpc-157-10mg\"\u003eBPC-157 10mg\u003c\/a\u003e · \u003ca href=\"\/products\/healing-blend-10mg-bpc-157-tb-500\"\u003eBPC-157 + TB-500 Healing Blend\u003c\/a\u003e · \u003ca href=\"\/products\/tb-500-10mg\"\u003eTB-500 10mg\u003c\/a\u003e · \u003ca href=\"\/products\/mots-c-10mg\"\u003eMOTS-c 10mg\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eShips from\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eBritish Columbia, Canada — free tracked shipping Canada-wide, dispatched within 48 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eRegulatory status\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#8a6318;font-weight:600\"\u003eInvestigational. Not approved by Health Canada, the FDA, the EMA or any other regulator. No DIN. All three components named in Health Canada advisory RA-81874 (9 Apr 2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eSport (WADA) status\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eContains WADA-prohibited substances: BPC-157 (class S0) and thymosin β4 \/ TB-500 (class S2). Not for use in or around competition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eIntended use\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003eLaboratory research only — in vitro and preclinical. Not a drug; not for human or veterinary use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#fbfaf7\"\u003e\n\u003cth style=\"text-align:left;padding:10px 12px;border:1px solid #e7e6e0;color:#16201a;font-weight:600\"\u003eFill note\u003c\/th\u003e\n\u003ctd style=\"padding:10px 12px;border:1px solid #e7e6e0;color:#5a6157\"\u003ePer-component amounts are the label (nominal) masses; measured content for each component is reported on the published COA, which also records an overall HPLC purity of 99.469% for this lot\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cdiv class=\"pp-faq\"\u003e\n\u003cdetails style=\"border-top:1px solid #e5e7eb\"\u003e\u003csummary style=\"font-weight:600;padding:14px 0;cursor:pointer\"\u003eWhat is in the GLOW blend, and why these three peptides specifically?\u003c\/summary\u003e\u003cdiv style=\"padding:0 0 16px;font-size:14px;line-height:1.7;color:#444\"\u003e\n\u003cp\u003eThe GLOW Blend is a single lyophilised vial containing three separate research peptides: \u003cstrong\u003eGHK-Cu\u003c\/strong\u003e, a copper-bound tripeptide (glycyl-L-histidyl-L-lysine); \u003cstrong\u003eBPC-157\u003c\/strong\u003e, a synthetic 15-residue gastric pentadecapeptide; and \u003cstrong\u003eTB-500\u003c\/strong\u003e, the research-market name tied to thymosin β4, a 43-residue actin-sequestering peptide. The owner-confirmed configuration is \u003cstrong\u003eGHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg\u003c\/strong\u003e, for a total of 70 mg, with the exact per-component mg values confirmed against this lot's certificate of analysis.\u003c\/p\u003e\n\u003cp\u003eThese three are grouped because they are the standard trio in \u003cstrong\u003eskin and connective-tissue repair research\u003c\/strong\u003e, and because their studied mechanisms sit on different parts of the same process rather than duplicating one another. GHK-Cu is the copper-tripeptide and extracellular-matrix arm — collagen, elastin and glycosaminoglycan signalling, copper transport and antioxidant pathways. BPC-157 is the angiogenic and cytoprotective arm, studied in tendon, ligament, muscle and gut-barrier models. TB-500 is the cytoskeletal arm, studied for actin regulation, cell migration and angiogenesis. The blend format lets a researcher expose one experimental system to all three pathways at once, rather than reconstituting and co-pipetting three separate vials and introducing three sets of handling and lot-matching variables.\u003c\/p\u003e\n\u003cp\u003eWhat the blend is \u003cem\u003enot\u003c\/em\u003e is a product with any demonstrated combined effect. There is no clinical trial of this three-peptide combination, no published pharmacology for the mixture as a mixture, and no approved indication for any of its parts. GLOW is a convenience format for parallel-pathway laboratory research — nothing on this page should be read as a claim that the combination does anything in a human body.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/details\u003e\n\u003cdetails style=\"border-top:1px solid #e5e7eb\"\u003e\u003csummary style=\"font-weight:600;padding:14px 0;cursor:pointer\"\u003eWhy combine GHK-Cu, BPC-157 and TB-500 in tissue-repair research?\u003c\/summary\u003e\u003cdiv style=\"padding:0 0 16px;font-size:14px;line-height:1.7;color:#444\"\u003e\n\u003cp\u003eThe honest answer is that the three address distinct, non-overlapping steps in tissue-repair models, so running them together lets an investigator look at several pathways in a single system. It is worth being precise about what each one contributes, because \"they all help healing\" is exactly the kind of flattening this page is built to avoid.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eGHK-Cu works on the matrix.\u003c\/strong\u003e In fibroblast culture it has been reported to stimulate collagen synthesis (Maquart et al., \u003cem\u003eFEBS Lett\u003c\/em\u003e 1988;238(2):343-346, PMID 3220688) and sulphated glycosaminoglycan synthesis, and it delivers copper — a cofactor several matrix enzymes require. It is the component that makes GLOW a \u003cem\u003edermal and extracellular-matrix\u003c\/em\u003e reagent rather than only a soft-tissue one.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eBPC-157 works on angiogenesis and cytoprotection.\u003c\/strong\u003e Rodent and in-vitro studies associate it with VEGFR2-pathway activation and increased endothelial and fibroblast activity (Hsieh et al., \u003cem\u003eJ Mol Med\u003c\/em\u003e 2017;95(3):323-333, PMID 27696202), and with tendon-cell outgrowth and migration (Chang et al., \u003cem\u003eJ Appl Physiol\u003c\/em\u003e 2011;110(3):774-780, PMID 21030672).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTB-500 works on the cytoskeleton and cell migration.\u003c\/strong\u003e Thymosin β4 sequesters G-actin and has been reported to accelerate wound closure and promote endothelial and keratinocyte migration and angiogenesis (Malinda et al., \u003cem\u003eJ Invest Dermatol\u003c\/em\u003e 1999;113(3):364-368, PMID 10469335; Goldstein et al., \u003cem\u003eTrends Mol Med\u003c\/em\u003e 2005;11(9):421-429, PMID 16099219).\u003c\/p\u003e\n\u003cp\u003eSo the combining rationale is mechanistic complementarity: matrix synthesis, vascular\/cytoprotective signalling, and cell migration are three requirements of a repair process, and GLOW puts a reagent for each in one vial. That rationale is a reason to \u003cem\u003estudy\u003c\/em\u003e the combination; it is not evidence that the combination produces an additive or synergistic result, which has not been demonstrated for these three together.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/details\u003e\n\u003cdetails style=\"border-top:1px solid #e5e7eb\"\u003e\u003csummary style=\"font-weight:600;padding:14px 0;cursor:pointer\"\u003eHow is a blend tested compared with a single peptide, and why is there no single purity number?\u003c\/summary\u003e\u003cdiv style=\"padding:0 0 16px;font-size:14px;line-height:1.7;color:#444\"\u003e\n\u003cp\u003eA single peptide is reported with one purity figure — for example \"99.6% by HPLC-UV at 214 nm\" — which is an area-percent ratio: the target peak's area divided by the total area of everything the detector sees in that one injection. That number is only meaningful when there is exactly one intended compound, so that everything else in the chromatogram is by definition an impurity.\u003c\/p\u003e\n\u003cp\u003eA blend breaks that logic. GLOW contains three intended peptides of very different mass (≈404, ≈1420 and ≈4963 g\/mol) and very different UV response, deliberately present at different amounts. A single \"purity\" percentage across all three would answer no useful question: it could not tell you whether the BPC-157 is actually present at its labelled mass, whether the copper complex has stayed intact, or whether one component has been substituted for a cheaper one. A high combined number could hide a missing component entirely.\u003c\/p\u003e\n\u003cp\u003eSo a blend is verified \u003cstrong\u003eper component\u003c\/strong\u003e. Each of the three peptides is confirmed by \u003cstrong\u003eidentity\u003c\/strong\u003e — typically mass spectrometry, which matches the measured mass to the expected mass of that specific peptide — and by \u003cstrong\u003econtent\u003c\/strong\u003e, a quantitative determination of how much of that component is actually in the vial against its labelled mg. The deliverable is a certificate that lists three identities and three content figures, not one purity percentage. This is exactly how we treat our other multi-component products, the \u003ca href=\"\/products\/healing-blend-10mg-bpc-157-tb-500\"\u003eBPC-157 + TB-500 Healing Blend\u003c\/a\u003e, the Wolverine blend and \u003ca href=\"\/products\/cjc-1295-ipamorelin\"\u003eCJC-1295 + Ipamorelin\u003c\/a\u003e.\u003c\/p\u003e\n\u003cp\u003eThat per-component certificate for lot glow70-0626-01 is now published, with its lot number and per-component content figures; the certificate also records an overall HPLC purity of 99.469%. When a vendor shows only a single purity percentage on a three-peptide blend with no per-component breakdown, that figure is either an aggregate that means little on its own or a number copied from one component and presented as if it covered the others — which is why we report the per-component results alongside it.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/details\u003e\n\u003cdetails style=\"border-top:1px solid #e5e7eb\"\u003e\u003csummary style=\"font-weight:600;padding:14px 0;cursor:pointer\"\u003eWhat is GHK-Cu, and what does the research actually show?\u003c\/summary\u003e\u003cdiv style=\"padding:0 0 16px;font-size:14px;line-height:1.7;color:#444\"\u003e\n\u003cp\u003eGHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine — molecular formula C\u003csub\u003e14\u003c\/sub\u003eH\u003csub\u003e22\u003c\/sub\u003eCuN\u003csub\u003e6\u003c\/sub\u003eO\u003csub\u003e4\u003c\/sub\u003e, CAS 89030-95-5, molecular weight approximately 403.9 g\/mol for the complex (the metal-free peptide GHK is 340.4 g\/mol, CAS 49557-75-7). The GHK sequence was first isolated from human plasma by Pickart and Thaler in 1973 and later identified as the tripeptide; it occurs naturally and its plasma level is reported to decline with age.\u003c\/p\u003e\n\u003cp\u003eThe research base is genuinely substantial for a peptide of this type, and it is mostly cell-culture and animal work plus topical cosmetic studies. In fibroblast cultures GHK-Cu has been reported to stimulate collagen synthesis (Maquart et al., \u003cem\u003eFEBS Lett\u003c\/em\u003e 1988;238(2):343-346, PMID 3220688) and sulphated glycosaminoglycan synthesis, and to affect small proteoglycans such as decorin. Review-level work by Pickart and colleagues collates roles in extracellular-matrix remodelling, antioxidant and anti-inflammatory signalling, and copper delivery (Pickart et al., \u003cem\u003eBiomed Res Int\u003c\/em\u003e 2015;2015:648108, PMID 26236730). A gene-expression review reports that GHK-Cu modulates a large fraction of assayed human genes using Connectivity Map data, with effects on matrix, antioxidant and DNA-repair pathways (Pickart \u0026amp; Margolina, \u003cem\u003eInt J Mol Sci\u003c\/em\u003e 2018;19(7):1987, PMID 29986520).\u003c\/p\u003e\n\u003cp\u003eTwo honest caveats. First, much of the human-relevant data is \u003cstrong\u003etopical\/cosmetic\u003c\/strong\u003e, not injectable-therapeutic data, so it does not transfer automatically to the kind of model a research buyer might build. Second, the broad gene-expression claims come from database-driven analyses and in-vitro systems, not controlled human outcome trials. GHK-Cu is the best-characterised of the three GLOW components in the sense of mechanism breadth, but \"well-studied mechanism\" is not \"proven therapeutic effect,\" and it is named in Health Canada advisory RA-81874 as an unauthorised peptide. A standalone version is \u003ca href=\"\/products\/ghk-cu-50mg\"\u003eGHK-Cu 50mg\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/details\u003e\n\u003cdetails style=\"border-top:1px solid #e5e7eb\"\u003e\u003csummary style=\"font-weight:600;padding:14px 0;cursor:pointer\"\u003eWhat is BPC-157, and what does the research actually show?\u003c\/summary\u003e\u003cdiv style=\"padding:0 0 16px;font-size:14px;line-height:1.7;color:#444\"\u003e\n\u003cp\u003eBPC-157 is a synthetic peptide of 15 amino acids — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — whose sequence corresponds to a fragment of a protein described in gastric juice and nicknamed \"body protection compound.\" Its molecular formula is C\u003csub\u003e62\u003c\/sub\u003eH\u003csub\u003e98\u003c\/sub\u003eN\u003csub\u003e16\u003c\/sub\u003eO\u003csub\u003e22\u003c\/sub\u003e, CAS 137525-51-0, molecular weight approximately 1419.6 g\/mol, PubChem CID 9941957. It is often supplied as an acetate salt and is reported to be unusually stable in gastric juice.\u003c\/p\u003e\n\u003cp\u003eThe research is almost entirely \u003cstrong\u003ein vitro and in rodents\u003c\/strong\u003e, and it is reasonably large at that level. The recurring themes are angiogenic signalling — one study links BPC-157's pro-angiogenic activity to VEGFR2 pathway activation and upregulation (Hsieh et al., \u003cem\u003eJ Mol Med\u003c\/em\u003e 2017;95(3):323-333, PMID 27696202) — and connective-tissue repair models, where BPC-157 has been reported to promote tendon-cell outgrowth, survival and migration (Chang et al., \u003cem\u003eJ Appl Physiol\u003c\/em\u003e 2011;110(3):774-780, PMID 21030672) and to upregulate the growth-hormone receptor in tendon fibroblasts (Chang et al., \u003cem\u003eMolecules\u003c\/em\u003e 2014;19(11):19066-19077, PMID 25415472). Narrative reviews collate these into a soft-tissue-healing hypothesis (Gwyer et al., \u003cem\u003eCell Tissue Res\u003c\/em\u003e 2019;377(2):153-159, PMID 31062091).\u003c\/p\u003e\n\u003cp\u003eThe caveats are serious and worth stating plainly. \u003cstrong\u003eHuman evidence is minimal\u003c\/strong\u003e: there is no completed, published, adequately powered human efficacy trial; the human record amounts to small retrospective and pilot reports and an unpublished Phase I. Because BPC-157 promotes angiogenesis, there is a theoretical, unresolved concern about promoting unwanted vascularisation, which is a reason it is a research reagent and not a therapeutic. It is named individually in Health Canada advisory RA-81874, and it is \u003cstrong\u003eprohibited in sport under WADA class S0\u003c\/strong\u003e (non-approved substances). A standalone version is \u003ca href=\"\/products\/bpc-157-10mg\"\u003eBPC-157 10mg\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/details\u003e\n\u003cdetails style=\"border-top:1px solid #e5e7eb\"\u003e\u003csummary style=\"font-weight:600;padding:14px 0;cursor:pointer\"\u003eWhat is TB-500 \/ thymosin β4, and what does the research actually show?\u003c\/summary\u003e\u003cdiv style=\"padding:0 0 16px;font-size:14px;line-height:1.7;color:#444\"\u003e\n\u003cp\u003e\"TB-500\" is a research-market name tied to \u003cstrong\u003ethymosin β4 (Tβ4)\u003c\/strong\u003e, a naturally occurring 43-residue, roughly 4.9 kDa peptide and the major G-actin-sequestering protein in many cell types. Full-length Tβ4 has molecular formula C\u003csub\u003e212\u003c\/sub\u003eH\u003csub\u003e350\u003c\/sub\u003eN\u003csub\u003e56\u003c\/sub\u003eO\u003csub\u003e78\u003c\/sub\u003eS, CAS 77591-33-4, molecular weight approximately 4963.4 Da, PubChem CID 16130300. Its core function is binding monomeric actin and regulating the pool available for filament assembly, which places it upstream of cell shape and cell migration.\u003c\/p\u003e\n\u003cp\u003eThe repair-research base is well-developed in vitro and in animals. Thymosin β4 has been reported to accelerate wound closure and to promote keratinocyte and endothelial cell migration, collagen deposition and angiogenesis in rodent and cell models (Malinda et al., \u003cem\u003eJ Invest Dermatol\u003c\/em\u003e 1999;113(3):364-368, PMID 10469335), and the mechanistic framing of an actin-sequestering protein \"moonlighting\" as a tissue-repair factor is set out in Goldstein et al. (\u003cem\u003eTrends Mol Med\u003c\/em\u003e 2005;11(9):421-429, PMID 16099219). A separate line of work reported cardiac cell migration and survival effects via integrin-linked kinase (Bock-Marquette et al., \u003cem\u003eNature\u003c\/em\u003e 2004;432(7016):466-472, PMID 15565145). Notably, the human clinical work that does exist — for example ophthalmic formulations for dry eye and neurotrophic keratopathy — used \u003cstrong\u003efull-length Tβ4\u003c\/strong\u003e, not the short fragment.\u003c\/p\u003e\n\u003cp\u003eThe important caveat for a blend buyer is identity, covered in its own FAQ below: the name \"TB-500\" historically denotes the short actin-binding fragment Ac-LKKTETQ (≈889 Da, residues 17–23), yet most research-grade \"TB-500\" is actually the full Tβ4 sequence, and the two are not interchangeable in an assay. Thymosin β4 is also \u003cstrong\u003eprohibited in sport under WADA class S2\u003c\/strong\u003e, and TB-500 is named in Health Canada advisory RA-81874. A standalone version is \u003ca href=\"\/products\/tb-500-10mg\"\u003eTB-500 10mg\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/details\u003e\n\u003cdetails style=\"border-top:1px solid #e5e7eb\"\u003e\u003csummary style=\"font-weight:600;padding:14px 0;cursor:pointer\"\u003eWhat does the evidence on the GLOW components NOT support?\u003c\/summary\u003e\u003cdiv style=\"padding:0 0 16px;font-size:14px;line-height:1.7;color:#444\"\u003e\n\u003cp\u003eThis is the most important FAQ on the page, because the gap between what is studied and what is proven is wide for all three peptides, and wider still for the combination.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNo evidence for the combination as a combination.\u003c\/strong\u003e There is no clinical trial, and no published pharmacology, for GHK-Cu + BPC-157 + TB-500 administered together. Any claim of synergy between the three is an inference from three separate literatures, not a measured result. Nothing licenses the idea that the blend does more than its parts.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNo adequate human efficacy data for BPC-157 or the TB-500 fragment.\u003c\/strong\u003e The BPC-157 record is dominated by rodent and in-vitro work with only small, mostly unpublished human reports; the injectable TB-500 fragment has essentially no controlled human efficacy trials. The human thymosin-β4 trials that exist used the full-length protein in specific formulations, which does not transfer to a research fragment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eGHK-Cu's strongest human data is topical.\u003c\/strong\u003e Much of the GHK-Cu human evidence is cosmetic skin work, not injectable-therapeutic outcome data, and the broad gene-expression findings come from database analyses and cell systems rather than controlled trials.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNo long-term safety data, and a real theoretical concern.\u003c\/strong\u003e Because both BPC-157 and TB-500 promote angiogenesis, there is an unresolved theoretical question about promoting unwanted vascular growth; no long-term safety dataset exists for any of the three as an injectable, and there is no pregnancy, paediatric or organ-impairment data. GHK-Cu additionally delivers copper, and copper balance itself is a variable a careful study must control for.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAnd none of it is approved.\u003c\/strong\u003e All three components are named in Health Canada's advisory RA-81874; the agency states they have not been assessed for safety, efficacy or quality, that they are illegal to sell for human use in Canada, and that a \"Research Use Only\" label does not change that. This is a laboratory reagent, and the evidence supports studying it, not using it.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/details\u003e\n\u003cdetails style=\"border-top:1px solid #e5e7eb\"\u003e\u003csummary style=\"font-weight:600;padding:14px 0;cursor:pointer\"\u003eHow does the GLOW blend differ from your Wolverine blend?\u003c\/summary\u003e\u003cdiv style=\"padding:0 0 16px;font-size:14px;line-height:1.7;color:#444\"\u003e\n\u003cp\u003eThey overlap on two of three components, and the difference is exactly the third. Our Wolverine blend is \u003cstrong\u003eBPC-157 + TB-500\u003c\/strong\u003e — the two soft-tissue and angiogenesis peptides — and it is the blend most researchers reach for when the model is tendon, ligament, muscle or gut-barrier repair. GLOW is \u003cstrong\u003eGHK-Cu + BPC-157 + TB-500\u003c\/strong\u003e: it keeps that soft-tissue pair and adds the copper tripeptide on top.\u003c\/p\u003e\n\u003cp\u003eAdding GHK-Cu changes the character of the reagent. GHK-Cu is the extracellular-matrix and dermal arm — collagen, elastin and glycosaminoglycan synthesis signalling, copper delivery and antioxidant pathways — so GLOW shifts the blend from a predominantly soft-tissue tool toward a \u003cstrong\u003eskin- and matrix-oriented\u003c\/strong\u003e one. If a model is primarily about dermal fibroblasts, matrix remodelling or copper-dependent processes, the GHK-Cu arm is the reason to choose GLOW over Wolverine. If the model is purely tendon or muscle, the two-component Wolverine (or the equivalent \u003ca href=\"\/products\/healing-blend-10mg-bpc-157-tb-500\"\u003eBPC-157 + TB-500 Healing Blend\u003c\/a\u003e) is the cleaner reagent, because it introduces one fewer variable and no copper into the system.\u003c\/p\u003e\n\u003cp\u003eThere is also a practical verification difference. A two-component blend is verified for two identities and two content figures; GLOW is verified for three. More components means more to confirm on the certificate and, in principle, more ways a fill can go wrong, which is one more reason the per-component COA matters. Both blends follow the same rule — identity and content confirmed per component — but GLOW's certificate simply has three lines where Wolverine's has two. Choosing between them is therefore a question about the model, not about which is \"stronger\": they are not ranked, they are scoped differently.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/details\u003e\n\u003cdetails style=\"border-top:1px solid #e5e7eb\"\u003e\u003csummary style=\"font-weight:600;padding:14px 0;cursor:pointer\"\u003eIs the TB-500 in this blend the full thymosin β4 or the Ac-LKKTETQ fragment?\u003c\/summary\u003e\u003cdiv style=\"padding:0 0 16px;font-size:14px;line-height:1.7;color:#444\"\u003e\n\u003cp\u003eThis is a real and under-discussed ambiguity, and the published COA is where it gets resolved for each lot. The name \"TB-500\" was originally applied to the short \u003cstrong\u003eAc-LKKTETQ\u003c\/strong\u003e peptide — an N-terminally acetylated 7-residue fragment corresponding to residues 17–23 of thymosin β4, molecular weight roughly 889 Da. That fragment contains the central actin-binding motif but lacks the rest of the full protein's surfaces.\u003c\/p\u003e\n\u003cp\u003eIn practice, most material sold on the research market as \"TB-500\" is the \u003cstrong\u003efull-length thymosin β4 sequence\u003c\/strong\u003e — 43 residues, molecular formula C\u003csub\u003e212\u003c\/sub\u003eH\u003csub\u003e350\u003c\/sub\u003eN\u003csub\u003e56\u003c\/sub\u003eO\u003csub\u003e78\u003c\/sub\u003eS, approximately 4963 Da. The two are chemically different species with a greater-than-fivefold mass difference, and they are not interchangeable in an assay: a mass-spectrometric identity check will immediately distinguish 889 Da from 4963 Da, and a method developed around one will not correctly quantify the other. Any content calculation, any molar normalisation and any comparison to the published Tβ4 literature depends on knowing which form is in the vial.\u003c\/p\u003e\n\u003cp\u003eIt matters for interpretation too. The human clinical work on thymosin β4 used the full-length protein; the research-market fragment has essentially no controlled human data of its own. So if a study intends to reference the Tβ4 literature, it needs the full-length form, and the COA has to say so.\u003c\/p\u003e\n\u003cp\u003eBecause of all this, we will not assert a form for the GLOW TB-500 component in the abstract. The published per-component certificate states the measured identity — full-length Tβ4 or the Ac-LKKTETQ fragment — for this lot, with the mass-spectrometric evidence behind it. If your protocol requires one form specifically, confirm it on the COA before relying on the vial.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/details\u003e\n\u003cdetails style=\"border-top:1px solid #e5e7eb\"\u003e\u003csummary style=\"font-weight:600;padding:14px 0;cursor:pointer\"\u003eIs the GLOW blend legal in Canada, and is it prohibited in sport?\u003c\/summary\u003e\u003cdiv style=\"padding:0 0 16px;font-size:14px;line-height:1.7;color:#444\"\u003e\n\u003cp\u003e\u003cstrong\u003eIt is not an approved product, and all three of its components are named by Health Canada.\u003c\/strong\u003e There is no Health Canada authorisation for GHK-Cu, BPC-157, TB-500 or any blend of them, and no Drug Identification Number. Health Canada's public advisory of 9 April 2026, \"Think twice before injecting peptides bought online\" (identification number RA-81874), lists GHK-Cu, BPC-157 and TB-500 individually among unauthorised peptides, alongside CJC-1295, DSIP, Epitalon, hCG, ipamorelin, KPV, melanotan I and II, MOTS-c, NAD+ and SS-31.\u003c\/p\u003e\n\u003cp\u003eThe advisory makes three points a research-peptide vendor has an obligation to reproduce rather than hide: these products have \u003cstrong\u003enot been assessed for safety, efficacy or quality\u003c\/strong\u003e; they are \u003cstrong\u003eillegal to sell for human use in Canada\u003c\/strong\u003e; and labelling a product \u003cstrong\u003e\"For Research Use Only\" does not make it legal\u003c\/strong\u003e to sell or use as a drug. The advisory names hormonal, metabolic, liver, kidney, clotting and tumour-growth risks, and the possibility of inconsistent ingredients or contaminants, among its concerns. We sell this vial as a laboratory reagent and not for injection into anyone, for any purpose. A per-component certificate addresses one of Health Canada's concerns — whether the contents are what the label says — and addresses none of the others.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIn sport, two of the three components are prohibited.\u003c\/strong\u003e BPC-157 is banned under WADA class S0 (non-approved substances), and thymosin β4 \/ TB-500 is banned under class S2 (peptide hormones, growth factors and related substances). The GLOW blend therefore contains WADA-prohibited substances and must not be used in or around competition by any athlete subject to anti-doping rules. GHK-Cu is not currently listed as a prohibited substance, but its presence does not offset the other two. Monitoring or non-listing of one component is never permission for the blend.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/details\u003e\n\u003cdetails style=\"border-top:1px solid #e5e7eb\"\u003e\u003csummary style=\"font-weight:600;padding:14px 0;cursor:pointer\"\u003eHow do you verify the identity and content of each component, and where is the COA?\u003c\/summary\u003e\u003cdiv style=\"padding:0 0 16px;font-size:14px;line-height:1.7;color:#444\"\u003e\n\u003cp\u003eEach GLOW lot carries a \u003cstrong\u003eper-component certificate of analysis\u003c\/strong\u003e. For each of the three peptides the certificate reports two distinct measurements. The first is \u003cstrong\u003eidentity\u003c\/strong\u003e: mass spectrometry matches the measured mass of each species to the expected mass of that specific peptide — approximately 404 Da for the GHK-Cu complex region, approximately 1420 Da for BPC-157, and either approximately 4963 Da (full-length thymosin β4) or approximately 889 Da (the Ac-LKKTETQ fragment) for the TB-500 component. The second is \u003cstrong\u003econtent\u003c\/strong\u003e: a quantitative determination of how many milligrams of each component are actually present, reported against the labelled per-component mass.\u003c\/p\u003e\n\u003cp\u003eThat is deliberately different from a single-peptide certificate, which reports one HPLC area-percent purity figure. For a three-peptide mixture a single purity number is not just unhelpful, it is misleading — it cannot reveal a missing or under-filled component, and a flattering aggregate can hide exactly the failure a buyer most needs to catch. So GLOW leads with three identities and three content figures rather than a single \"verified purity\" value; the certificate does, in addition, record an overall HPLC purity of 99.469% for this lot.\u003c\/p\u003e\n\u003cp\u003eThis lot's certificate is published: lot glow70-0626-01 carries its per-component identity and content figures and an overall HPLC purity of 99.469%, backed by a document rather than an unsupported claim. This follows the same discipline as the rest of our catalogue, where a certified lot carries a named laboratory and a verifiable report number and an uncertified one says so plainly. The GLOW COA is indexed on our \u003ca href=\"\/pages\/lab-results\"\u003elab results page\u003c\/a\u003e with the rest of the catalogue, and the methodology walkthrough in \u003ca href=\"\/blogs\/news\/how-to-read-peptide-coa\"\u003ehow to read a peptide COA\u003c\/a\u003e explains how to read a per-component certificate.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/details\u003e\n\u003cdetails style=\"border-top:1px solid #e5e7eb\"\u003e\u003csummary style=\"font-weight:600;padding:14px 0;cursor:pointer\"\u003eHow should the GLOW blend be stored and handled in the laboratory?\u003c\/summary\u003e\u003cdiv style=\"padding:0 0 16px;font-size:14px;line-height:1.7;color:#444\"\u003e\n\u003cp\u003e\u003cstrong\u003eLyophilised, sealed and desiccated: −20 °C for long-term holding, 2–8 °C for short-term, protected from light.\u003c\/strong\u003e That is the research convention for unformulated peptides and it is what the specification table states. Sealed vials tolerate ambient shipping temperatures for the transit period without meaningful loss; the cold requirement applies to holding, not to the journey.\u003c\/p\u003e\n\u003cp\u003eA blend adds one consideration a single peptide does not have: the three components have different stability profiles, so the storage regime has to be conservative enough for the most fragile of them. The copper complex in GHK-Cu can in principle dissociate or participate in copper-catalysed oxidation, and thymosin β4 is a large, flexible peptide with its own susceptibilities, so there is no \"store to the most robust component\" shortcut — the cold, dark, dry default protects all three.\u003c\/p\u003e\n\u003cp\u003eAfter reconstitution with sterile or bacteriostatic water, hold at 2–8 °C and \u003cstrong\u003eminimise freeze–thaw cycling\u003c\/strong\u003e, which is the most common avoidable cause of peptide loss. Divide a reconstituted stock into single-use aliquots at first preparation so no working volume is thawed twice, and do not return thawed material to the freezer. Avoid vigorous agitation, which can drive adsorption and aggregation at air–liquid interfaces — a realistic loss pathway for peptides of this size.\u003c\/p\u003e\n\u003cp\u003eWe publish no figure for how long the reconstituted blend remains intact, because no stability study we can verify has been published for this three-peptide mixture in solution at any concentration, buffer or temperature — and because the three components would not necessarily degrade on the same timeline, a single \"good for N days\" claim for the blend would be a guess. Suppliers quoting a specific number of days for a blend are quoting something they have not measured. We stock \u003ca href=\"\/products\/bacteriostatic-water-3ml\"\u003ebacteriostatic water 3ml\u003c\/a\u003e for laboratory reconstitution.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/details\u003e\n\u003cdetails style=\"border-top:1px solid #e5e7eb\"\u003e\u003csummary style=\"font-weight:600;padding:14px 0;cursor:pointer\"\u003eHow fast do you ship, and is delivery free across Canada?\u003c\/summary\u003e\u003cdiv style=\"padding:0 0 16px;font-size:14px;line-height:1.7;color:#444\"\u003e\n\u003cp\u003eShipping is \u003cstrong\u003efree and tracked, Canada-wide, on every order, with no minimum\u003c\/strong\u003e. Orders are dispatched \u003cstrong\u003ewithin 48 hours\u003c\/strong\u003e, Monday to Friday, from our facility in \u003cstrong\u003eBritish Columbia\u003c\/strong\u003e. Because the vial is already in Canada there is no international leg, no customs clearance and no brokerage fee on a domestic order, and no risk of a shipment being held or seized at a border — the single most common failure point for peptides bought from overseas vendors.\u003c\/p\u003e\n\u003cp\u003eThe GLOW blend is \u003cstrong\u003ein stock and ships within 48 hours\u003c\/strong\u003e, each vial accompanied by the per-component certificate of analysis for its lot — the whole point of a per-component certificate is that it accompanies the vial it describes. Vials leave sealed and tracking is issued at dispatch, so the shipment can be followed from our facility to delivery.\u003c\/p\u003e\n\u003cp\u003eOne cosmetic note specific to this blend: GHK-Cu gives the lyophilised powder and the reconstituted solution a characteristic \u003cstrong\u003epale-blue tint\u003c\/strong\u003e, which is expected from the copper complex and is not a sign of degradation, contamination or a problem with the vial. A colourless GLOW vial would be more surprising than a blue one. Sealed vials tolerate ambient shipping temperatures for the transit period without meaningful loss; the cold-storage requirement applies to holding the material once it arrives, not to the journey itself. Current transit estimates by province are on our \u003ca href=\"\/pages\/shipping\"\u003eshipping page\u003c\/a\u003e, and tracking questions can go to \u003ca href=\"mailto:info@thepeptide.ca\"\u003einfo@thepeptide.ca\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/details\u003e\n\u003cdetails style=\"border-top:1px solid #e5e7eb;border-bottom:1px solid #e5e7eb\"\u003e\u003csummary style=\"font-weight:600;padding:14px 0;cursor:pointer\"\u003eWhat is your return policy if a vial arrives damaged?\u003c\/summary\u003e\u003cdiv style=\"padding:0 0 16px;font-size:14px;line-height:1.7;color:#444\"\u003e\n\u003cp\u003eReport damage in transit or non-delivery to \u003ca href=\"mailto:info@thepeptide.ca\"\u003einfo@thepeptide.ca\u003c\/a\u003e \u003cstrong\u003ewithin 48 hours of the expected delivery date\u003c\/strong\u003e, with photographs of the packaging and the vial where applicable, and we will resolve it — a replacement or a refund, as the situation warrants. A cracked, leaking or visibly compromised vial should be reported before anything is opened, so the state it arrived in can be documented.\u003c\/p\u003e\n\u003cp\u003eSealed, unopened vials are exchangeable within \u003cstrong\u003e14 days\u003c\/strong\u003e of delivery. There are no refunds or exchanges on product that has been opened, reconstituted or otherwise prepared: once a seal is broken we cannot verify the handling history, and a reagent of unknown temperature and light exposure is not one we will put back into circulation for another researcher.\u003c\/p\u003e\n\u003cp\u003eThis distinction matters more for a blend than for a single peptide. A single peptide vial that is returned unopened can in principle be re-checked against its own certificate; an opened GLOW vial cannot be re-qualified at all, because the three components do not share a degradation profile and there is no single purity measurement that would confirm all three survived whatever handling occurred. Verifying a used multi-peptide vial would mean re-running a full per-component identity-and-content panel on material of unknown provenance, which is neither practical nor a basis on which we would resell. For that reason the sealed-only rule is firm for this product. The pale-blue colour of the GLOW powder, incidentally, is not a defect and is not grounds for return — it is the expected appearance of the GHK-Cu copper complex. Full terms are on our \u003ca href=\"\/policies\/refund-policy\"\u003erefund policy\u003c\/a\u003e page.\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/details\u003e\n\u003c\/div\u003e","brand":"ThePeptide","offers":[{"title":"Default Title","offer_id":50592979386438,"sku":"GLOW-70MG","price":119.99,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0734\/3020\/4486\/files\/GLOWBLEND.png?v=1791516794","url":"https:\/\/thepeptide.ca\/products\/glow-blend","provider":"ThePeptide","version":"1.0","type":"link"}